Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.

Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Gerritsen M, van der Meer LT, Williams O, Hoogerbrugge PM, Scheijen B, van Leeuwen FN.

Exp Hematol. 2018 Apr;60:57-62.e3. doi: 10.1016/j.exphem.2018.01.006. Epub 2018 Feb 8.

PMID:
29408281
2.

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer LT, Pieters R, Escherich G, Horstmann MA, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper RP, Hoogerbrugge PM, den Boer ML, van Leeuwen FN.

Haematologica. 2017 Mar;102(3):541-551. doi: 10.3324/haematol.2016.153023. Epub 2016 Dec 15.

3.

Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development.

Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Havinga J, Rouault JP, Hoogerbrugge PM, van Leeuwen FN, Scheijen B.

Haematologica. 2016 Jul;101(7):e272-6. doi: 10.3324/haematol.2015.139675. Epub 2016 Apr 1. No abstract available.

4.

Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.

Yuniati L, van der Meer LT, Tijchon E, van Ingen Schenau D, van Emst L, Levers M, Palit SA, Rodenbach C, Poelmans G, Hoogerbrugge PM, Shan J, Kilberg MS, Scheijen B, van Leeuwen FN.

Oncotarget. 2016 Jan 19;7(3):3128-43. doi: 10.18632/oncotarget.6519.

5.

The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.

Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y, Sonneveld E, Hoogerbrugge PM, van Kessel AG, van Leeuwen FN, Kuiper RP.

PLoS Genet. 2012;8(2):e1002533. doi: 10.1371/journal.pgen.1002533. Epub 2012 Feb 16.

6.

Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita.

Jongmans MC, Verwiel ET, Heijdra Y, Vulliamy T, Kamping EJ, Hehir-Kwa JY, Bongers EM, Pfundt R, van Emst L, van Leeuwen FN, van Gassen KL, Geurts van Kessel A, Dokal I, Hoogerbrugge N, Ligtenberg MJ, Kuiper RP.

Am J Hum Genet. 2012 Mar 9;90(3):426-33. doi: 10.1016/j.ajhg.2012.01.004. Epub 2012 Feb 16.

7.

BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia.

van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, Scheijen B, Waanders E, van Reijmersdal SV, Gilissen C, van Kessel AG, Hoogerbrugge PM, van Leeuwen FN.

Blood. 2010 Jun 10;115(23):4810-9. doi: 10.1182/blood-2009-05-223081. Epub 2010 Mar 30.

8.

Gfi1 ubiquitination and proteasomal degradation is inhibited by the ubiquitin ligase Triad1.

Marteijn JA, van der Meer LT, van Emst L, van Reijmersdal S, Wissink W, de Witte T, Jansen JH, Van der Reijden BA.

Blood. 2007 Nov 1;110(9):3128-35. Epub 2007 Jul 23.

9.

Diminished proteasomal degradation results in accumulation of Gfi1 protein in monocytes.

Marteijn JA, van der Meer LT, Van Emst L, de Witte T, Jansen JH, van der Reijden BA.

Blood. 2007 Jan 1;109(1):100-8. Epub 2006 Aug 3.

10.

The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells.

Marteijn JA, van Emst L, Erpelinck-Verschueren CA, Nikoloski G, Menke A, de Witte T, Löwenberg B, Jansen JH, van der Reijden BA.

Blood. 2005 Dec 15;106(13):4114-23. Epub 2005 Aug 23.

11.

Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction.

Raaijmakers MH, van Emst L, de Witte T, Mensink E, Raymakers RA.

Exp Hematol. 2002 May;30(5):481-7.

PMID:
12031655
12.

A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.

van Oosterhout YV, van Emst L, Schattenberg AV, Tax WJ, Ruiter DJ, Spits H, Nagengast FM, Masereeuw R, Evers S, de Witte T, Preijers FW.

Blood. 2000 Jun 15;95(12):3693-701.

13.

Anti-idiotypic immunization provides protection against lethal endotoxaemia in BALB/c mice.

Cornelissen JJ, Maassen K, van Emst L, Weers PM, Harmsen M, Benaissa-Trouw BJ, Oosterlaken TA, Kraaijeveld CA, Verhoef J.

Immunology. 1993 Aug;79(4):673-80.

Supplemental Content

Loading ...
Support Center